Home / Markets / Mark To Market /  Aurobindo shares rebound on termination of agreement to acquire Cronus

Aurobindo shares rebound on termination of agreement to acquire Cronus

Aurobindo Pharma's European Union sales rose 19.7% year-on-year during Q1 and were supported by emerging market revenue growth of 13.7% year-on-year. (Photo: Mint)Premium
Aurobindo Pharma's European Union sales rose 19.7% year-on-year during Q1 and were supported by emerging market revenue growth of 13.7% year-on-year. (Photo: Mint)

  • Aurobindo's June quarter results were hit by soft performance in the US, which contribute about half to total sales. Pricing pressure in key products is said to have impacted the performance. Inventory build-up was cited as another reason

Aurobindo Pharma Ltd. has terminated its binding agreement to acquire 51% stake in Cronus Pharma Specialities India Private Limited  Rs420 crore. While the Aurobindo management had expected to grow the business (to about $100 million over the next three years), there were concerns about low revenue base ($13million in FY21) and thereby on deal valuation as well. With the agreement now called off, the stock soared 6% in early trade on Monday.

The surge in the stock comes after a period of lacklustre trade. In August will last week, the stock had corrected more than 20% to 52-week lows. The company’s soft June quarter performance had failed to impress the Street and one of the company’s manufacturing facility receiving observations from the US FDA (Food and Drug Administration) had added to investor concerns.

June quarter results were hit by soft performance in the US, which contribute about half to the company’s total sales. Pricing pressure in key products is said to have impacted the performance. Inventory build-up was cited as another reason for the decline in sales. Aurobindo’s US revenues declined 7.4% sequentially to $364 million in the June quarter, below the estimated $397 million. Injectable sales also dropped 8.8% sequentially as demand for elective surgeries remained weak. Investors thereby will be watchful for a rebound in the company’s US sales. The resolution of the US FDA observations will also be monitored.

“We believe Aurobindo’s US portfolio has lower concentration, pricing risk compared to peers, given it is well-diversified (top 25 products accounts for 32% of the revenue)" said analysts at HDFC Securities Ltd.

The company, however, remains on a strong footing in Europe, the next important region for Aurobindo after the US. European Union sales rose 19.7% year-on-year during Q1 and were supported by emerging market revenue growth of 13.7% year-on-year.

“Potential value unlocking of the injectables business and resolution of US FDA facilities are the key near-term trigger," said analysts at HDFC Securities in their recent report.

 

ABOUT THE AUTHOR

Ujjval Jauhari

Ujjval Jauhari is a deputy editor at Mint, with over a decade of experience in newspapers and digital news platforms. He is skilled in storytelling, reporting, analysing and writing about stocks, investment ideas, markets, corporates and more. He is based in New Delhi.
Know your inner investor Do you have the nerves of steel or do you get insomniac over your investments? Let’s define your investment approach.
Take the test
Catch all the Business News, Market News, Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.
More Less

Recommended For You

Trending Stocks

×
Get alerts on WhatsApp
Set Preferences My ReadsWatchlistFeedbackRedeem a Gift CardLogout